Excision's cutting edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.
We are the first company to remove HIV genomes from animals and generate functional cures for HIV.
Targets non-human viral genomes minimizing chance of off-target cuts
Removes non-human DNA to return the genome to normal or near-normal
Excision products require one-time gene edit to remove the viral genome permanently
Jennifer Doudna, Ph.D., CRISPR Co-inventor
UC Berkeley, 2020
988 Market Street
San Francisco, CA 94102
1755 N. 13th Street #274
Philadelphia, PA 19122
© 2020 Excision BioTherapeutics. All Rights Reserved.